Compare Matson Inc (MATX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Nuwellis Inc — how do they compare? Matson Inc trades at $222.69 (market cap $6.61B), while Nuwellis Inc trades at $2.85 (market cap $1.09M). The key difference: Matson Inc is far larger — about 6064.2× Nuwellis Inc's market cap, and Matson Inc pays a 0.7% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| MATX | NUWE | |
|---|---|---|
Market Cap | $6.61B | $1.09M |
Sector | Technology | Technology |
52-Week High | $223.55 | $527.46 |
52-Week Low | $88.05 | $2.80 |
Enterprise Value | $7.21B | -$722.58K |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains a bullish technical outlook with strong moving averages and key support at $214. The company demonstrates solid fundamentals with a P/E of 16.48, net income margin of 12.92%, and consistent earnings beats in recent quarters. Recent news highlights preliminary Q2 2026 results expecting EPS of $4.12-$4.30 and a dividend increase to $0.38 per share, reflecting management confidence.
The investment outlook remains positive given analyst consensus of 63.64% buy ratings, robust cash flow from operations, and strategic fleet modernization. Key risks include exposure to Pacific trade volatility and potential economic slowdowns impacting shipping demand. The stock's current valuation and growth trajectory present a compelling opportunity for investors seeking stable dividends and earnings growth in the shipping sector.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
